If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Feb 2022 11:47

RNS Number : 8892B
e-Therapeutics plc
16 February 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B2823H99

Issuer Name

E-THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-Feb-2022

6. Date on which Issuer notified

16-Feb-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.000000

< 3%

Position of previous notification (if applicable)

0.000000

4.005700

4.005700

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Sub Total 8.A

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

5168858

1.004500

Sub Total 8.B1

5168858

1.004500%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Matthew Allen01727895011

12. Date of Completion

16-Feb-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAFAKFLSAEFA
Date   Source Headline
16th Dec 202012:38 pmRNSHolding(s) in Company
8th Dec 202011:07 amRNSCOVID-19 Project Update
21st Oct 20209:06 amRNSIssue of Equity
12th Oct 20203:15 pmRNSHolding(s) in Company
12th Oct 20207:00 amRNSAppointment of Ali Mortazavi as CEO
12th Oct 20207:00 amRNSInterim Results for six months ended 31 July 2020
5th Oct 202012:07 pmRNSNotice of Interim Results
28th Sep 20207:00 amRNSExpansion of Scientific Advisory Board
28th Jul 20205:46 pmRNSHolding(s) in Company
23rd Jul 202010:03 amRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20207:01 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSDirector/PDMR Shareholding
15th Jul 20207:00 amRNSDirector/PDMR Shareholding
14th Jul 20204:49 pmRNSExercise of Broker Option and Total Fundraise
9th Jul 20204:47 pmRNSExercise of Broker Option
8th Jul 20204:41 pmRNSSecond Price Monitoring Extn
8th Jul 20204:36 pmRNSPrice Monitoring Extension
8th Jul 20202:05 pmRNSSecond Price Monitoring Extn
8th Jul 20202:00 pmRNSPrice Monitoring Extension
8th Jul 20207:00 amRNSResult of Retail Offer
7th Jul 20205:46 pmRNSRetail Offer
7th Jul 20205:42 pmRNSFundraise of up to £12.4 million
22nd Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20207:00 amRNSCollaboration with Galapagos
3rd Jun 20205:52 pmRNSHolding(s) in Company
2nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:36 pmRNSPrice Monitoring Extension
2nd Jun 20202:30 pmRNSResults of 2020 Annual General Meeting
28th May 20207:04 amRNSExpansion into RNAi and creation of SAB
18th May 20204:41 pmRNSSecond Price Monitoring Extn
18th May 20204:37 pmRNSPrice Monitoring Extension
18th May 202011:05 amRNSSecond Price Monitoring Extn
18th May 202011:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSExperimental testing initiated with WuXi AppTec
15th May 20205:17 pmRNSAnnual General Meeting – Change of Arrangement
15th May 20203:12 pmRNSe-therapeutics to present at Shares Evening
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 202011:05 amRNSSecond Price Monitoring Extn
16th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSAppointment of Chief Business Officer
23rd Mar 20207:00 amRNSAnti-viral drug discovery initiative
17th Mar 20207:00 amRNSResults for the year ended 31 January 2020
11th Mar 20201:30 pmRNSNotification of Full Year Results Date
20th Feb 20206:09 pmRNSHolding(s) in Company
18th Feb 202012:02 pmRNSHolding(s) in Company
11th Feb 202010:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.